PD98059

Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 147 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NUjkd5RPTnWwY4Tpc44hSXO|YYm= MnO0NlUh|ryP Mm\WNUBp MnvXZox2dnS|IITo[UBDY2GfUD3pcoR2[2WmIHnuZ5Jm[XOnIHnuJJBpd3OyaH:tR4hsOSCjbnSgdIhwe3Cqbz3FVmsh\XiycnXzd4lwdg>? NID3RmozPTd4OUG4NS=>
MCF-7  M4rC[mZ2dmO2aX;uJGF{e2G7 M1jyUFExKM7:TR?= MYixJIg> NGHzT41qdmirYnn0d{BKVC1zOD3lcohidmOnZDDj[YxtKG2rZ4LheIlwdg>? NXnqPG85OjV5MkewNVE>
HepG2  MYrGeY5kfGmxbjDBd5NigQ>? NYLie3I6OTBizszN MXW1JIg> MVvicI9kc3NicHjvd5Bpd3K7bHH0[YQhVUGSS4OgbY5lfWOnZDDifUBmgG:pZX7veZMhXEeILd8yNS=> Mn3sNlU2PjB2OEi=
HepG2  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\5UGw4OjBizszN NW\ZZm1nOjRiaB?= NXfnSYJYe3WycILld5NmeyCWR1[t{tIyNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDDpcpZie2mxbh?= MXyyOVU3ODR6OB?=
MDA-MB-231 MV7GeY5kfGmxbjDBd5NigQ>? NWXlUlN7OjVizszN MXeyMVMhcA>? MXrk[YNz\WG|ZYOgdE1GWktzL{KgZY5lKFNzMEDBOEBmgHC{ZYPzbY9v MYqyOVU2PTh5NR?=
SW480 MV7GeY5kfGmxbjDBd5NigQ>? MV:yNOKh|ryP MmPJNeKhcA>? MXLy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFHUSlMheHKxdHXpci=> MlLXNlU1PDd6MU[=
HCT-15 MYrGeY5kfGmxbjDBd5NigQ>? M{OzfFEhcA>? MlzJZZR1\W63YYTld{BRT0V{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb:Kh MXWyOVQ{OTR{NR?=
HCT-15 NHHoWlNCeG:ydH;zbZMhSXO|YYm= MlfRNUBp NFqyUXVi[m:uaYPo[ZMhfGinIIDyc5Rm[3SrdnWg[YZn\WO2czDv[kBRT0V{wrDh[4FqdnO2IHP1doN2dWmwLXnu[JVk\WRiYYDvdJRwe2m| NWLzU3hSOjV2M{G0NlU>
786-O NXjpVHUzSXCxcITvd4l{KEG|c3H5 M1TIXFUxyqEQvF2= NYjO[HZlOjRiaB?= M13KSZBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D M3zOXVI1PTB6NEe2
A498 NYf0eYpvSXCxcITvd4l{KEG|c3H5 M3nW[lUxyqEQvF2= MkPyNlQhcA>? NYToRopkeG:2ZX70bYF1\XQEoITo[UBxem9vYYDvdJRwfGmlIHXm[oVkfHNib3[gUmM> NGewdGEzPDVyOES3Oi=>
NHBE M1fa[GZ2dmO2aX;uJGF{e2G7 NFPNZ4czNzJyIN88US=> NELPR4UzKGh? MUjheJRmdnWjdHXzJGlNNTN|IIP0bY12dGG2ZXSgR3hEVDhxSVytPEB{\WO{ZYTpc44> MkTCNlQ1Pzl3Mk[=
A375 MWTD[YxtKEmwdnHzbY9vKEG|c3H5 MlHxNVDjiJN{MDFCuW0> NHzab4IzPCCq NHW0S2Nz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25? NUe4WnZYOjR2Nk[wN|Y>
HBMEC NXPPfYtITnWwY4Tpc44hSXO|YYm= Mlr5NVAh|ryP MoO0NUBp NGfITm5jdG:la4OgWmVITi2rbnT1Z4VlKEWyaFGyJIV5eHKnc4Ppc44> NFjuO20zPDR3OEm4Ni=>
HPAEpiCs  MV3GeY5kfGmxbjDBd5NigQ>? NHfFXpQ{OCEQvF2= NGrZRYcyKGh? M13GRolvcGmkaYTzJHRPTi4QsTDzeIlufWyjdHXkJJA1Oi:yNESgUWFRUyCyaH;zdIhwenmuYYTpc44> NVnyPHZzOjR2NEG4O|A>
BeWo NYXxbJZmTnWwY4Tpc44hSXO|YYm= Mo\uNVDDqM7:TR?= NEHLcHYzKGh? MXXpcohq[mm2czDFVmsyNzJ? NX\PZVNUOjR2M{O4OFY>
PC3  MULBdI9xfG:|aYOgRZN{[Xl? M2niOVUxKM7:TR?= NX3WN3B7OC53IHi= MnnpbY5pcWKrdIOgUWh[NTR2OT3pcoR2[2WmIHHwc5B1d3Orc9Mg NETOUJAzPDR{NEi4PS=>
HGC-27 M3rnZ2Fxd3C2b4Ppd{BCe3OjeR?= NUfzcGM3OSEEtV2= NIHsNGUyKGh? MUjzeZBxemW|c3XzJHJCTDByMTDwcJV{KE2NLUKyNFYucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ MknxNlQ1OTZ|NEm=
MCF-7 M3rhXmZ2dmO2aX;uJGF{e2G7 Moj1NVDDqM7:TR?= MkHuNVAwOzBibXnu M{W2NpJm\HWlZYOgeIhmKFWWUD3k[ZBmdmSnboSgSXJMKHCqb4PwbI9zgWyjdHnvci=> M1X5VVI1OzlyOEG5
HUVECs MV3GeY5kfGmxbjDBd5NigQ>? M{Hxe|ExyqEQvF2= Ml7wNUBp NGrqfmJqdmirYnn0d{B1cGViSFTMJJJm\HWlZXSgR29ZNTJiZYjwdoV{e2mxbjDhcoQhWEeLLUKgdoVt\WG|ZR?= M1fWTFI1Ozh3MUC5
HeLa NIDYc|FHfW6ldHnvckBCe3OjeR?= M3P5NVUxKM7:TR?= MWiwMlUhcA>? MXHicI9kc3NiVGLYMVEhdnWlbHXhdkBucWe{YYTpc44h[W6mIGTYUmlRKGSxd36tdoVofWyjdHnvci=> NXjPPWFSOjR|N{[4Nlc>
HL-60  MljVSpVv[3Srb36gRZN{[Xl? MWSxNE8zOCEQvF2= NGfuc5cyKGh? NH3rSplqdmirYnn0d{B1cGYEoF6uJINpcW6nboPpd4V5fHKjY4VCpIlv\HWlZXSg[Iln\mW{ZX70bYF1cW:wIHnueI8h\3KjboXsc4N6fGW| NWXzb4dFOjR|NUewNlA>
HL-60 MkHhSpVv[3Srb36gRZN{[Xl? MorPNkDDvU1? MV6xOkBp MVfEUXNQ NUi4N493cW6qaXLpeJMhfGinIHHzd49kcWG2aX;uJI9nKHCVNkKxJHJi\i1zIHHu[EBPTkGWY{OsJIFv\CC2aHWgVmEucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YhdnWlbHXhdkBPTkGWY{O= NHTPdo4zPDN|MEC2PC=>
HEK 293 NEXublZHfW6ldHnvckBCe3OjeR?= MXGxNEDPxE1? M1TwWVUhcA>? MmfMSG1UVw>? MmnFbY5pcWKrdIOgW451NWmwZIXj[YQh|rJvY3H0[Y5qdi:WQ1[0JIFkfGm4aYT5JIFv\CCwdXPs[YFzKM7{LXPheIVvcW5iYXPjeY12dGG2aX;u NX3oe4JDOjR|MkSzOlY>
HEK 293 MkXESpVv[3Srb36gRZN{[Xl? M3\TS|ExKM7:TR?= NV7N[I9JPSCq NXfqVFdyTE2VTx?= MYDzeZBxemW|c3XzJJRp\SCFUmSgZYN1cX[rdIm= NV3SUXoxOjR|MkSzOlY>
SW480 MVvGeY5kfGmxbjDBd5NigQ>? MmCxNVAh|ryP Moe5NlAhcA>? Mk\wSG1UVw>? MYTzeZBxemW|c3XzJJRp\SCFUmSgZYN1cX[rdIm= NVXEXlhvOjR|MkSzOlY>
HCSMCs MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\ieIhbOTBizszN NInSOYYzPCCq NYm4N3RF[myxY3vzJGZCSlB2LXnu[JVk\WRiSFPBV21EKHC{b3zp[oVz[XSrb36= MmHWNlQ{OTJ|OEG=
PANC-1 NIfwTI9HfW6ldHnvckBCe3OjeR?= MVyyNEDPxE1? NV6zOnY2PDhiaB?= M2Th[YlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJO6VPkRiaX6gdoV{eG:wc3WgeI8hfGinIGDQRXLPvMLiYXfvcol{fMLi NGrybXUzPDJ7NEGzNy=>
A549 NFfoWphHfW6ldHnvckBCe3OjeR?= M2PZO|MxKM7:TR?= MYiwMlUhcA>? NV7UNZNDTE2VTx?= Mnq4bY5pcWKrdIOgeIhmKHSqcn;tZolvNWmwZIXj[YQhUUxvOD;DXGNNQC2OdXOgZYN1cX[rdIm= M4[1cFI1Ojd5Nkm2
A549 M{TqSWZ2dmO2aX;uJGF{e2G7 MX6zNEDPxE1? M4\QTFAvPSCq M{\UUmROW09? NY\sRZFIcW6qaXLpeJMhfGi{b33ibY4ucW6mdXPl[EBEN0WEUN8yJHRpejJ|NdMgdIhwe3Cqb4L5cIF1cW:w M{mzfFI1Ojd5Nkm2
MC-3 MlXpRZBweHSxc3nzJGF{e2G7 MXWxNEDPxE1? MlnENlQhcA>? MYnwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m|IHnuJEBk\Wyucx?= MUmyOFI4ODV{Mx?=
Raji  MV\GeY5kfGmxbjDBd5NigQ>? MoHRNVAh|ryP NUDQRYRVOSCq NUHT[XlG[myxY3vzJIh{SkGIRjDpcoR2[2WmIFXyb|EwOiCyaH;zdIhwenmuYYTpc44> NGG2OYwzPDJ4OU[zNC=>
Raji  NHiyUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj4NVAh|ryP NUWybpdyOSCq M2e4XIlvcGmkaYTzJJRp\SCkYYPhcEBweiCqc1LBSmYue3SrbYXsZZRm\CClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fS=> MoDnNlQzPjl4M{C=
HT29 NYPNO4JITnWwY4Tpc44hSXO|YYm= MmDSNVAh|ryP M37vNFIhcA>? MWPpcohq[mm2czDv[kBLSUt{LDDFVmsyNzJiYX7kJHNVSVR|IIDoc5NxcG:{eXzheIlwdg>? NVG0dpd{OjR{NkWyPVM>
HepG2 M17kXmFxd3C2b4Ppd{BCe3OjeR?= MlnXNlAh|ryP M3r0blI1KGh? Ml7tbY5pcWKrdIOgSXJMOS9{IIDoc5NxcG:{eXzheIlwdiCjbnSg[Y5p[W6lZYOgWmIyNWmwZIXj[YQh[XCxcITvd4l{ NUfK[GRDOjR{NEe5NFk>
HepG2 NVv6XmtQTnWwY4Tpc44hSXO|YYm= NV7wPVVbOjBizszN NIPSXY8zKGh? M1rqNIVvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm= MXWyOFI1PzlyOR?=
TE4 M1;kOmZ2dmO2aX;uJGF{e2G7 NHPYd2gzOC93MD:xNFAh|ryP M4PKbFQ5KGh? NVXUSlQ3TE2VTx?= M1zZVolvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M17VNlI1OjR2MEKz
TE1 NF65[ZZHfW6ldHnvckBCe3OjeR?= NYfNR2lwOjBxNUCvNVAxKM7:TR?= MlLXOFghcA>? NImwWYpFVVOR M4XWT4lvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{i5T|I1OjR2MEKz
KYSE30 MVTGeY5kfGmxbjDBd5NigQ>? M2fHPFIxNzVyL{GwNEDPxE1? Ml[wOFghcA>? MoniSG1UVw>? NGXKO5JqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYeyOFI1PDB{Mx?=
TE1 NGq3SIdHfW6ldHnvckBCe3OjeR?= NEjSVlY2OCEQvF2= MmrrOFghcA>? M2G4UGROW09? M4rQ[JVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEiOQTDjcIF{eyCL MX:yOFI1PDB{Mx?=
TE3 NWPhZmk4TnWwY4Tpc44hSXO|YYm= NETSRnE2OCEQvF2= MYq0PEBp MkG5SG1UVw>? MkHseZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MkHhNlQzPDRyMkO=
TE4 MofrSpVv[3Srb36gRZN{[Xl? MYS1NEDPxE1? MnHJOFghcA>? NHe4UGxFVVOR MnHleZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? M2S2XFI1OjR2MEKz
TE5 NFXOS2ZHfW6ldHnvckBCe3OjeR?= NIHFdY02OCEQvF2= NUXFNnhuPDhiaB?= NFSybGpFVVOR NUC2ellxfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= NYXSZYVvOjR{NESwNlM>
KYSE30 MX\GeY5kfGmxbjDBd5NigQ>? M1LHTVUxKM7:TR?= MYe0PEBp MXLEUXNQ MoLDeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MUSyOFI1PDB{Mx?=
MKN7 MVrGeY5kfGmxbjDBd5NigQ>? MmroOVAh|ryP MojOOFghcA>? MUjEUXNQ MV\pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| M1P5cVI1OjR2MEKz
OE19 NHHp[HZHfW6ldHnvckBCe3OjeR?= MlvWOVAh|ryP M3XqW|Q5KGh? M2GzSmROW09? NUTJdo41cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MWCyOFI1PDB{Mx?=
KATOIII  NVSwUVFITnWwY4Tpc44hSXO|YYm= NFPKWpE2OCEQvF2= MV60PEBp MlTiSG1UVw>? M3zkbIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO= M3[1cVI1OjR2MEKz
NCI-N87  M2HNXmZ2dmO2aX;uJGF{e2G7 MU[1NEDPxE1? NWO0SnJ1PDhiaB?= NXfLV49VTE2VTx?= NVPHS285cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NFzIZoszPDJ2NECyNy=>
NUGC3 MoPVSpVv[3Srb36gRZN{[Xl? MVO1NEDPxE1? Mlv4OFghcA>? M1XpNGROW09? MWXpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| MmXNNlQzPDRyMkO=
NUGC2 NULSR2RiTnWwY4Tpc44hSXO|YYm= MmPrOVAh|ryP NH72ems1QCCq MojxSG1UVw>? MoXtbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MWGyOFI1PDB{Mx?=
SGC-7901  MmGzRZBweHSxc3nzJGF{e2G7 MXqyNEDPxE1? Ml\UNlQhcA>? M2LJSYlvcGmkaYTzJGNRNW2nZHnheIVlKGGyb4D0c5Nqew>? NHHtXnUzPDJ2MUO1NS=>
MG-63 NGS1Z3ZHfW6ldHnvckBCe3OjeR?= MVmyNEDPxE1? NEjVO4UxNjViaB?= MULicI9kc3NidHjlJGNJNWmwZIXj[YQheGixc4Doc5J6dGG2ZXSgSWxMOSCycn;0[YlvKGW6cILld5Nqd25? NFTleVMzPDJ|OU[0NC=>
ARPE-19 NXjhW4d2TnWwY4Tpc44hSXO|YYm= MYqyNEDPxE1? NVvk[nA5OC53IHi= M{TRdolvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=> MlW2NlQzOjd7MUi=
CRL-2302 NXrVd20zTnWwY4Tpc44hSXO|YYm= MlrpNlAh|ryP MY[wMlUhcA>? NEn1Z2NqdmirYnn0d{BCeGWuaX6tbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gSZJsKGGwZDDBb5Q> NUnY[ZRwOjR{Mke5NVg>
MCF-7 M4LnNWZ2dmO2aX;uJGF{e2G7 MmjnNlAh|ryP NXjqbJRpOSCq M2DRT4Fjd2yrc3jld{BmgHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIVlKEWUSzDjc{11emWjdH3lcpQhf2m2aDDjc45rfWejdHW= M3fZclI1OjF4Mki5
MCF-7 MkfERZBweHSxc3nzJGF{e2G7 M1;iPVIxKM7:TR?= M2f1UlEhcA>? NH3hNoVqdmO{ZXHz[ZMh[2G|cHHz[U06KGWweont[UBi[3Srdnn0fS=> MkTENlQzOTZ{OEm=
DLD-1  M2L3dmZ2dmO2aX;uJGF{e2G7 NVfHZlNROjEEoN88US=> NFHiZZI1QCCq NHLpUJRz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM> Mn62NlQzOTF3OEG=
HT-29 NXrEb5J6TnWwY4Tpc44hSXO|YYm= MmHSNlDDqM7:TR?= MX:0PEBp NWTQOVN2emWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE M{\ifFI1OjFzNUix
7402 MVHBdI9xfG:|aYOgRZN{[Xl? M4LTS|MxKM7:TR?= MoXzOUBl NYf6RVBx\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? NXvtb|I3OjR{MUGyOVM>
7721 NX;FPJo6SXCxcITvd4l{KEG|c3H5 M2XJN|MxKM7:TR?= MmrNOUBl M4PVOYRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> NH\PclEzPDJzMUK1Ny=>
SGC7901  NWHmNoJISXCxcITvd4l{KEG|c3H5 M{D6XFUxyqEQvF2= NXewRWJSOjRxNEivO|IhcA>? NEL4OVVFVVOR NGLWOnFqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT|Ihe2iUTlG= MWiyOFE4QDJ2MB?=
SMMC7721 MXXGeY5kfGmxbjDBd5NigQ>? NIT1foYzPS93MDFOwG0> MXSyOEBp M1HkRZN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YheC2Da4Sgc5IheC2HUluxM|LDqA>? MW[yOFE3QDB3Nh?=
MCF-7 NYPIXIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;IZVNyOTBizszN MmjzOFhp NED6UoJFVVOR Mn32doV3\XK|ZYOgRm5HNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5Q> MXKyOFE3OzRyNB?=
Caco-2 MnfKSpVv[3Srb36gRZN{[Xl? MlrrOVDDqM7:TR?= M{HMclQ5cA>? MWTEUXNQ NHiwbFhmdmijbnPld{B1cGVibWLORUBt\X[nbIOgc4bDqFOFTl6xRUxHYFmGMz|CpGxEXC{EoFzPXEzDqEiLRkPBMOKhYkdzNj|CpHBFTT[DwrDhcoTDqEyJQVzTNVbDqGenbnXzxsBkdy22cnXheIVlKHerdHigSIV5 NXz1N4NYOjRzNkG2PVU>
HAECs NUX2WHRTTnWwY4Tpc44hSXO|YYm= M1vFUVExKM7:TR?= M1rv[FEhcA>? MYdCpIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQhUUODTT2xJIFv\CCYQ1HNMVEh\XiycnXzd4lwdg>? NFrIbYQzPDF|NE[1Oy=>
Ca9-22 NWnCfW12TnWwY4Tpc44hSXO|YYm= NEP2O4s{KM7:TR?= NWPjU4FmOSCq MknqZYJwdGm|aHXzJJRp\SCjYnnsbZR6KG:oIFjiVkB1dyCrbnT1Z4UhUUxvODDwdo9lfWO2aX;u MXuyOFEzPjV|Mh?=
Ca9-22 NHrIOJFHfW6ldHnvckBCe3OjeR?= NVHVOZdSOyEQvF2= MWmxM|IhcA>? Mkj5doVlfWOnczDIZnIucW6mdXPl[EBCXEZvMjDwbI9{eGixconsZZRqd25? NGi1VJAzPDF{NkWzNi=>
AGS Ml3QSpVv[3Srb36gRZN{[Xl? MonENVAh|ryPwrC= MljQNE42KGh? NUPCXIZmcW6qaXLpeJMhfGinIIXwdoVofWyjdHnvckBw\iC2aHWgTWwuQCCpZX7l MW[yOFExPjF4Nh?=
Caco-2  MX7BdI9xfG:|aYOgRZN{[Xl? MY[xNOKh|ryP MX2yOOKhcA>? Mniy[IVkemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgOU1HXQ>? MkjDNlQxQTV6NkO=
HCT-8 M1z5cmFxd3C2b4Ppd{BCe3OjeR?= NF[yWHAyOMLizszN MUSyOOKhcA>? MXPk[YNz\WG|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTC1MWZW MV[yOFA6PTh4Mx?=
A549 Moq1SpVv[3Srb36gRZN{[Xl? MXe1NOKh|ryP MYqyJIg> M3PT[YJtd2OtczDFVmsheGixc4Doc5J6dGG2aX;uJI1m\GmjdHXkJIJ6KDFuMj3OVS=> Mnz6NlQxPjd5Mke=
HPMC MlvCSpVv[3Srb36gRZN{[Xl? M3\JOFExyqEQvF2= MoGwOFghcA>? NFHPdZlz\X[ncoPld{B1cGViY3jhcodmeyCrbjDj[YxtKG2xcoDoc4xw\3liaX7keYNm\CCkeTDIS3BFWw>? MkXMNlQxPDJ6M{i=
HPMC NIm5NI1CeG:ydH;zbZMhSXO|YYm= NYewUVFPOTEEoN88US=> M1XMXlI1yqCq MVfy[ZZmenOnczDk[YNz\WG|ZTDpckBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JGhIWESV NIm1VWEzPDB2MkizPC=>
MGC803  M3[5W2Fxd3C2b4Ppd{BCe3OjeR?= MXyyNOKh|ryP NGjMeFIyKGh? MVjpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBKTk5vzsJCpIFv\CB34pEyMWRHXVJ? NEnoSZIzPDB{N{e1NC=>
SGC7901 NIfi[ZZCeG:ydH;zbZMhSXO|YYm= NGr3Z4ozOMLizszN NGTMTJEyKGh? M2TnZolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?= M3fhTFI1ODJ5N{Ww
COLO205 MYHBdI9xfG:|aYOgRZN{[Xl? MVixNE8zOC92MDFOwG0> M2PHbVI1KGh? NXzFdo0{cW6mdXPld{BFVkFibHHk[IVzKG[xcn3heIlwdg>? M3qwbVI1ODF7MUC4
G292  M1KzSmFxd3C2b4Ppd{BCe3OjeR?= MlnXN|DDqM7:TR?= NGjsS4kzKGh? Ml;JdoV{fG:{ZYOgZ4Fxe2GrY3nuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NYOz[Y1YOjRyMUK5N|A>
BxPC-3 NFTxPHVHfW6ldHnvckBCe3OjeR?= M1PFb|ExKM7:TdMg MV:2JIg> NGjMXFhqdmO{ZXHz[UBucVJvMUSzJIV5eHKnc4Ppc44> MUSyN|k4OzdzMB?=
HPAF-II M33ST2Z2dmO2aX;uJGF{e2G7 NWnORmFQOTBizszNxsA> MnPGOkBp NX2yfI1bcW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9v NX\sZnZ2OjN7N{O3NVA>
HL-60 NEfoR2JCeG:ydH;zbZMhSXO|YYm= NX\rblJ6PTEEoN88US=> MnX0NUBp MUjy[ZNkfWW|IFLBNVQ2KG2nZHnheIVlKGGyb4D0c5Nqew>? MmC4NlM6PDh5NUG=
HepG2 MVXGeY5kfGmxbjDBd5NigQ>? M{XWN|QxKM7:TR?= M1ziZ|YwOTJiaB?= NHjpWGJqdmirYnn0d{B1cGViaX7jdoVie2Vib3[gdE1GWktzIHHu[EBxNWNvSoXuJJBzd3SnaX6g[ZhxemW|c3nvckBjgSCSTB?= M{\vU|I{QTR{OEWx
HUVECs NVzkflRNTnWwY4Tpc44hSXO|YYm= NX:5U3hxOjVizszN NVnIWVBrOSCq NVXUWIs1cW6lcnXhd4UhVkZvzsrCJJA3PSCwdXPs[YFzKHS{YX7zcI9k[XSrb36= NFjYfHQzOzlyMUCwPC=>
LNCaP  NGPzeVRHfW6ldHnvckBCe3OjeR?= MYexNEDPxE4EoB?= MUGxJIg> NHjjXIZl\WO{ZXHz[ZMhfGinIFXHSkB2eHKnZ4XsZZRm\CCyLWnCMVE> MoL5NlM5Ozh|MUi=
HL60  NVfETWh7TnWwY4Tpc44hSXO|YYm= NWryWoF4OjEEoN88US=> M4fEbFczKGh? MU\EUXNQ NVP1[ndZcW6qaXLpeJMh\GG|YYTpcoljNWmwZIXj[YQhS0RzMXKg[ZhxemW|c3nvci=> MYKyN|gzPTV6NR?=
NB4  NGjobJJHfW6ldHnvckBCe3OjeR?= Mnn2NVAh|ryPwrC= NYPteFhtPzJiaB?= Ml7jSG1UVw>? M1ztcolvcGmkaYTzJIRie2G2aX7pZk1qdmS3Y3XkJGNFOTGkIHX4dJJme3Orb36= NXP5[WNXOjN6MkW1PFU>
EPOR/CR3 MmDxSpVv[3Srb36gRZN{[Xl? MlLkOVDDqM7:TR?= M3jkeVMhcA>? MljJdoVlfWOnczDFVG8h[W6mL3;yJGlNNTNvaX7keYNm\CC2aHWgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wwrC= MV6yN|gzODd|MR?=
HUASMCs M4nKbmZ2dmO2aX;uJGF{e2G7 MUSxNEDPxE4EoB?= MWCyOEBp NEWyfXhlcW2rbnnzbIV{KEGwZzDJTU1k[XW|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC= MlPlNlM5OTZ2Nki=
HUASMCs M4DLPGZ2dmO2aX;uJGF{e2G7 M4TMdVExKM7:TdMg MVmyOEBp M1TFfIlvcGmkaYTzJGFv\yCLST3pcoR2[2WmIFXST|EwOiCyaH;zdIhwenmuYYTpc44hdGW4ZXy= MknXNlM5OTZ2Nki=
SGC7901 MmfFSpVv[3Srb36gRZN{[Xl? MmPqNVAh|ryPwrC= NFLZcXczPCCq MVLpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM|I> NVroTGRLOjN5OUK1PFg>
MKN45 Ml7TSpVv[3Srb36gRZN{[Xl? NHzXUHEyOCEQvF5CpC=> NEn5UVEzPCCq NXvXNJFRcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheGixc4Doc5J6dGG2ZXSgSXJMOS9{ M3TIWFI{Pzl{NUi4
SGC7901 NGnWfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxNEDPxE4EoB?= M4nabVI1NzR6L{eyJIg> MV\pcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? NGn3fnEzOzd7MkW4PC=>
MKN45 NHvJb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\uN|ExKM7:TdMg NHvuU|kzPC92OD:3NkBp MVnpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? NF;qNpMzOzd7MkW4PC=>
SGC7901 MVTBdI9xfG:|aYOgRZN{[Xl? MmHsNVAh|ryPwrC= M{nnNVI1KGh? M1K2O4lv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| M{XHeFI{Pzl{NUi4
MKN45 MUTBdI9xfG:|aYOgRZN{[Xl? NEHyd3cyOCEQvF5CpC=> NXTVbGRxOjRiaB?= MlrkbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? NXzBVmlbOjN5OUK1PFg>
BxPC-3 cells Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDGXXczOMLizszN NX7QdpZGOC53IHi= NXjDSZVZcW6qaXLpeJMhXkWJRj3BMZJm\3WuYYTl[EBJXV[HQzDndo94fGhiYX7kJJR2[mViZn;ycYF1cW:wIHnu[JVk\WRiYomgVGFTNTJiQWC= MWeyN|c3PDB2Nh?=
NB4  Mn7TRZBweHSxc3nzJGF{e2G7 NXSwRVZsOTBxMkCvOlAh|ryP NXjO[2ZWOS53IHi= MVPEUXNQ NYfEWGJM\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDQZYNtcXSjeHXs M4PVXlI{PzN3NUSx
HepG2  MmjISpVv[3Srb36gRZN{[Xl? MnHhNlDDqM7:TR?= NIrV[|UzPCCq M2j2U4lvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu MUSyN|cxPzZyOR?=
HUVECs MYLBdI9xfG:|aYOgRZN{[Xl? MYSyM|Qh|ryP NYTLeGhPOjRxNEigbC=> M1PHWolv\HWlZYOgZ4VtdCCmZXH0bC=> NW\UboNzOjN5MEe1NlA>
KG-1  M2jmcmFxd3C2b4Ppd{BCe3OjeR?= MW[yNOKh|ryP NVLGdmRROTJiaB?= NG\Gc4dmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy MYKyN|cxPjZ7MR?=
AML 1# NH7JbohCeG:ydH;zbZMhSXO|YYm= M4\MNlIxyqEQvF2= NILs[4wyOiCq NHW0VWxmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy NH61OnAzOzdyNk[5NS=>
A2780  NEDmVGZHfW6ldHnvckBCe3OjeR?= MnLZNlDDqM7:TR?= M1HWXlEhcA>? NIP5eXFjdG:la4OgSHRETC2rbnT1Z4VlKESUNTDlfJBz\XO|aX;u Ml;5NlM3QTZ6NkK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; 

PubMed: 17482134     


ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading.

p-JNK / JNK / Cyclin D1 ; 

PubMed: 17482134     


Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading.

p-HER2 / HER2 ; 

PubMed: 24244023     


TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. 

MMP9 / XIAP / VEGF ; 

PubMed: 29695559     


SK-Hep1 cells were treated 10 μM PD98059 for 48 h.  Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.

17482134 24244023 29695559
In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID